Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 15/20 | 0.52 |
| ▸ | CA1 | P00915 | 14/20 | 0.52 |
| ▸ | CA9 | Q16790 | 14/20 | 0.52 |
| ▸ | CA12 | O43570 | 11/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.51 |
| ▸ | CA4 | P22748 | 3/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.49 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.48 |
| ▸ | IKBKB | O14920 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL185757 | 0.91 | CA2 (0.61) | PTGES2CA2CA1CA9CA12 | |
| SCHEMBL6256281 | 0.85 | CA2 (0.53) | PTGES2CA2CA1CA9CA12 | |
| SCHEMBL8473263 | 0.83 | CA2 (0.52) | PTGES2CA2CA1CA9CA12 | |
| SCHEMBL7188667 | 0.83 | PTGES2 (0.64) | PTGES2CA2CA1CA9CA12 | |
| SCHEMBL6168875 | 0.83 | CA2 (0.68) | PTGES2CA2CA1CA9CA12 | |
| SCHEMBL6252199 | 0.80 | CA1 (0.59) | PTGES2CA2CA1CA9CA12 | |
| SCHEMBL1926937 | 0.80 | CA2 (0.67) | PTGES2CA2CA1CA9CA12 | |
| SCHEMBL28802276 | 0.79 | CA1 (0.59) | CA2CA1CA9CA12CA14 | |
| SCHEMBL27901606 | 0.79 | CA1 (0.62) | CA2CA1CA9CA12CA14 | |
| SCHEMBL8196817 | 0.77 | CA2 (0.61) | CA2CA1CA9CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2146987-B1 | OXAZOLIDINONE ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-02 | — | — | EP | disclosed |
| EP-2137141-B1 | BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | UNIV ABERDEEN (GB) | 2015-12-02 | — | — | EP | disclosed |
| US-8524778-B2 | Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents | PIMCO 2664 LIMITED (GB) | 2013-09-03 | — | — | US | disclosed |
| US-20100286266-A1 | Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2010-11-11 | — | — | US | disclosed |
| EP-2137141-A1 | BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | The University Court of The University of Aberdeen (GB) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008114022-A1 | BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286266-A1 | Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents | ARSA, SOST, AHR | PTGES2 1754/4885CA2 3111/4885CA1 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.